Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 94

Related Citations for PubMed (Select 22776707)

1.

Centralised multidisciplinary re-evaluation of diagnostic procedures in patients with newly diagnosed Hodgkin lymphoma.

Stevens WB, van Krieken JH, Mus RD, Arens AI, Mattijssen V, Oosterveld M, de Kruijf EJ, de Vries F, Koster A, van der Maazen R, Raemaekers J.

Ann Oncol. 2012 Oct;23(10):2676-81. Epub 2012 Jul 9.

2.

[Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma].

Niu Y, Shi YK, He XH, Feng FY, Zhou LQ, Gu DZ.

Zhonghua Zhong Liu Za Zhi. 2008 Aug;30(8):630-4. Chinese.

PMID:
19102946
3.

Hodgkin lymphoma in Tyrol-a population-based study.

Fong D, Steurer M, Greil R, Gunsilius E, Spizzo G, Gastl G, Tzankov A.

Ann Hematol. 2009 May;88(5):449-56. doi: 10.1007/s00277-008-0618-1. Epub 2008 Oct 10.

PMID:
18846373
4.

[Treatment results of stage IA Hodgkin lymphoma: a report of 97 cases].

Tan WY, Hu DS, Zeng FY, Song QB, Hu S, Wei L, Zhou LQ.

Ai Zheng. 2007 Dec;26(12):1360-4. Chinese.

PMID:
18076802
5.

Comparison of favorable early-stage hodgkin's lymphoma treatments: a single-institution review.

Samant R, Alomary I, Alsaeed E, Al-Jasir B, Bence-Bruckler I, Cross P, Genest P, Huebsch L.

Int J Radiat Oncol Biol Phys. 2010 Mar 15;76(4):1166-70. doi: 10.1016/j.ijrobp.2009.03.070. Epub 2009 Aug 19.

PMID:
19695788
6.

Nodular lymphocyte predominant Hodgkin lymphoma behaves as a distinct clinical entity with good outcome: evidence from 14-year follow-up in the West of Scotland Cancer Network.

Farrell K, McKay P, Leach M.

Leuk Lymphoma. 2011 Oct;52(10):1920-8. doi: 10.3109/10428194.2011.584993. Epub 2011 Jun 12.

PMID:
21663507
7.

Management of Hodgkin lymphoma.

Ansell SM, Armitage JO.

Mayo Clin Proc. 2006 Mar;81(3):419-26. Review.

PMID:
16529147
8.

Comparison of initial characteristics and long-term outcome of patients with lymphocyte-predominant Hodgkin lymphoma and classical Hodgkin lymphoma at clinical stages IA and IIA prospectively treated by brief anthracycline-based chemotherapies plus extended high-dose irradiation.

Feugier P, Labouyrie E, Djeridane M, Jenabian A, Dubruille V, Berthou C, Ghandour C, Desablens B, Chaït Y, Casassus P, Delwail V, Ifrah N, Le Mevel A, Lamy T, Brière J, Colonna P, Andrieu JM.

Blood. 2004 Nov 1;104(9):2675-81. Epub 2004 Jul 1.

9.

Predictive factors for radiation pneumonitis in Hodgkin lymphoma patients receiving combined-modality therapy.

Fox AM, Dosoretz AP, Mauch PM, Chen YH, Fisher DC, LaCasce AS, Freedman AS, Silver B, Ng AK.

Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):277-83. doi: 10.1016/j.ijrobp.2011.05.078. Epub 2011 Oct 20.

PMID:
22019238
11.

[Treatment results of Hodgkin's lymphoma].

Aleknavicius E, Valuckas KP, Aleknaviciene B, Norkiene L, Smailyte G.

Medicina (Kaunas). 2009;45(8):615-23. Lithuanian.

12.

First-line treatment of Hodgkin's lymphoma.

Klimm B, Engert A, Diehl V.

Curr Hematol Rep. 2005 Jan;4(1):15-22. Review.

PMID:
15610655
13.

Clinical presentation and outcome in lymphocyte-predominant Hodgkin's disease.

Bodis S, Kraus MD, Pinkus G, Silver B, Kadin ME, Canellos GP, Shulman LN, Tarbell NJ, Mauch PM.

J Clin Oncol. 1997 Sep;15(9):3060-6.

PMID:
9294468
14.

Risk-adapted therapy with three or six cycles of doxorubicin/bleomycin/vinblastine/dacarbazine plus involved-field radiation therapy in Hodgkin lymphoma, based on prognosis at diagnosis and early response: results from the GATLA study.

Pavlovsky S, Corrado C, Pavlovsky MA, Prates MV, Zoppegno L, Giunta M, Cerutti I, Palomino E, Pagani F, Lastiri F, Bar D, Bezares RF, Avila G.

Clin Lymphoma Myeloma Leuk. 2010 Jun;10(3):181-5. doi: 10.3816/CLML.2010.n.028.

PMID:
20511162
15.

Long-term outcomes after high dose therapy and autologous haematopoietic cell rescue for refractory/relapsed Hodgkin lymphoma.

Minn AY, Riedel E, Halpern J, Johnston LJ, Horning SJ, Hoppe RT, Goodman KA.

Br J Haematol. 2012 Nov;159(3):329-39. doi: 10.1111/bjh.12038. Epub 2012 Sep 12.

PMID:
22966754
16.

Favorable early-stage Hodgkin lymphoma.

Yahalom J.

J Natl Compr Canc Netw. 2006 Mar;4(3):233-40. Review.

PMID:
16507270
17.

A systematic overview of radiation therapy effects in Hodgkin's lymphoma.

Gustavsson A, Osterman B, Cavallin-Ståhl E.

Acta Oncol. 2003;42(5-6):589-604. Review.

PMID:
14596517
18.

Stanford V program for locally extensive and advanced Hodgkin lymphoma: the Memorial Sloan-Kettering Cancer Center experience.

Edwards-Bennett SM, Jacks LM, Moskowitz CH, Wu EJ, Zhang Z, Noy A, Portlock CS, Straus DJ, Zelenetz AD, Yahalom J.

Ann Oncol. 2010 Mar;21(3):574-81. doi: 10.1093/annonc/mdp337. Epub 2009 Sep 16.

20.

Lymphocyte-predominant Hodgkin lymphoma--clinical features and treatment outcomes from a 30-year experience.

Jackson C, Sirohi B, Cunningham D, Horwich A, Thomas K, Wotherspoon A.

Ann Oncol. 2010 Oct;21(10):2061-8. doi: 10.1093/annonc/mdq063. Epub 2010 Mar 23.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk